background
goal
studi
determin
iv
magnesium
use
sever
pediatr
asthma
reduc
time
medic
readi
discharg
patient
bronchiol
ad
support
care
compar
singl
dose
mgkg
iv
magnesium
sulfat
vs
placebo
acut
bronchiol
patient
receiv
bronchodil
therapi
nebul
hyperton
salin
day
dexamethason
eczema
andor
famili
histori
asthma
time
medic
readi
discharg
primari
efficaci
outcom
bronchiol
sever
score
need
infirmari
hospit
admiss
clinic
revisit
within
week
secondari
outcom
cardiorespiratori
instabl
onset
safeti
outcom
result
total
previous
healthi
infant
diagnos
bronchiol
age
day
month
median
month
enrol
approxim
onehalf
patient
eczema
andor
famili
histori
asthma
posit
find
nasopharyng
viru
swab
geometr
mean
time
medic
readi
discharg
h
ci
magnesiumtr
patient
h
ci
patient
receiv
placebo
ratio
ci
p
mean
bronchiol
sever
score
time
similar
two
group
frequenc
clinic
visit
subsequ
week
respect
also
similar
fifteen
magnesium
recipi
vs
five
placebo
recipi
readmit
infirmari
hospit
within
week
p
acut
cardiorespiratori
side
effect
report
conclus
iv
magnesium
provid
benefit
patient
acut
bronchiol
may
harm
despit
mani
studi
test
investig
therapi
mainstay
bronchiol
treatment
remain
support
care
includ
supplement
oxygen
hydrat
reevalu
nebul
hyperton
salin
previous
suggest
favor
affect
length
stay
subsequ
shown
benefit
howev
subset
infant
bronchiol
histori
eczema
andor
famili
histori
asthma
firstdegre
rel
seem
benefit
corticosteroid
treatment
reduc
rate
admiss
length
stay
time
readi
discharg
moder
sever
exacerb
asthma
somewhat
older
children
iv
magnesium
likewis
decreas
admiss
rate
length
ed
stay
reason
iv
magnesium
knowledg
never
previous
test
control
trial
bronchiol
might
similarli
benefici
especi
subset
eczema
andor
strong
famili
histori
asthma
given
high
clinic
burden
bronchiol
increas
rate
requir
hospit
admiss
absenc
new
inexpens
readili
avail
therapi
iv
magnesium
test
infant
moder
sever
ill
bronchiol
doubleblind
placebocontrol
studi
studi
conduct
octob
may
short
stay
unit
pediatr
emerg
center
hamad
gener
hospit
pediatr
emerg
facil
state
qatar
center
serv
averag
patient
annual
manag
bed
short
stay
infirmari
unit
patient
admit
ill
sent
home
requir
icu
stepdown
care
recent
length
stay
bronchiol
rang
h
infant
age
month
present
treatment
moder
sever
viral
bronchiol
elig
studi
moder
sever
bronchiol
requir
prodrom
histori
consist
viral
upper
respiratori
tract
infect
follow
wheez
andor
crackl
auscult
wang
bronchiol
sever
score
present
wang
bronchiol
sever
score
rang
four
variabl
receiv
score
increas
score
denot
wors
statu
patient
exclud
studi
one
follow
characterist
preterm
birth
week
gestat
histori
wheez
steroid
use
within
h
present
obtund
progress
respiratori
failur
requir
icu
admiss
histori
apnea
within
h
present
oxygen
satur
room
air
histori
diagnosi
chronic
lung
diseas
congenit
heart
diseas
immunodefici
exposur
varicella
within
day
enrol
known
magnesium
calcium
metabol
disturb
known
advers
reaction
magnesium
sulfat
written
inform
consent
sought
one
parent
legal
guardian
consecut
elig
patient
obtain
particip
studi
consent
form
approv
hamad
medic
corpor
institut
review
board
number
patient
examin
present
examin
area
center
requir
treatment
observ
admit
short
stay
infirmari
unit
consecut
patient
bronchiol
assess
studi
elig
within
h
initi
physician
assess
patient
written
inform
consent
obtain
underw
plain
chest
radiographi
nasopharyng
swab
gather
rapid
respiratori
viru
panel
capabl
identifi
multipl
respiratori
virus
multiplex
realtim
polymeras
chain
reaction
assay
abi
analyz
appli
biosystem
random
stratifi
two
group
patient
histori
eczema
andor
known
parent
full
sibl
prior
physician
diagnosi
asthma
patient
without
block
random
use
alloc
steril
stock
solut
ml
magnesium
sulfat
ident
volum
salin
placebo
use
prepar
fresh
blind
syring
mgml
given
mlkg
intraven
use
syring
pump
min
design
accord
random
tabl
provid
unblind
pharmacist
withheld
treatment
assign
other
patient
connect
cardiorespiratori
monitor
immedi
start
infus
h
monitor
safeti
infant
posit
histori
eczema
andor
known
parent
full
sibl
prior
physician
diagnosi
asthma
also
start
oral
dexamethason
mgkg
first
day
mgkg
daili
day
studi
patient
receiv
ml
nebul
hyperton
salin
ml
epinephrin
given
interv
throughout
infirmari
stay
use
protocol
treatment
studi
site
period
studi
conduct
hyperton
salin
solut
prepar
daili
steril
condit
studi
patient
inhal
therapi
deliv
tightfit
face
mask
pressur
oxygen
flow
meter
set
lmin
nebul
epinephrin
mlkg
minimum
dose
ml
maximum
dose
ml
allow
ml
hyperton
salin
hourli
maximum
frequenc
addit
treatment
eg
supplement
oxygen
hydrat
antibiot
given
discret
treat
physician
magnesium
infus
withdrawn
clinic
deterior
determin
warrant
icu
admiss
patient
judg
readi
discharg
treat
physician
determin
patient
need
supplement
oxygen
feed
adequ
without
iv
fluid
minim
absent
wheez
crackl
chest
retract
provid
oxygen
satur
wang
score
discharg
patient
sent
home
salbutamol
metereddos
inhal
appropriatelys
aerochamb
mask
attach
forest
laboratori
although
evid
base
benefit
nebul
epinephrin
discharg
salbutamol
method
commonli
use
elsewher
center
period
studi
conduct
telephon
followup
studi
nurs
mandatori
daili
week
discharg
patient
could
return
pediatr
emerg
center
earlier
requir
primari
outcom
time
medic
readi
discharg
secondari
outcom
bronchiol
sever
score
h
also
week
infirmari
discharg
record
patient
requir
hospit
admiss
readmiss
short
stay
infirmari
unit
site
initi
treatment
well
patient
visit
clinic
revisit
pediatr
emerg
center
ill
requir
admiss
daili
telephon
call
week
studi
nurs
record
inform
gener
wellb
work
breath
feed
toler
vomit
diarrhea
need
physician
visit
hospit
time
readi
discharg
plot
use
univari
kaplanmei
surviv
analysi
depict
proport
patient
remain
infirmari
group
acceler
failur
time
model
log
logist
function
analysi
use
calcul
compar
geometr
mean
time
readi
discharg
treatment
group
accord
ratio
mean
bronchiol
sever
score
group
plot
categor
continu
variabl
express
frequenc
percentag
mean
ae
sd
valu
descript
statist
summar
baselin
demograph
clinic
characterist
quantit
variabl
mean
two
independ
group
analyz
use
unpair
student
test
wilcoxon
ranksum
test
associ
fig
two
enrol
infant
could
includ
analysi
one
diagnos
immunodefici
one
discharg
medic
advic
infant
episod
remain
patient
random
receiv
iv
magnesium
histori
eczema
andor
famili
histori
asthma
total
patient
receiv
placebo
histori
eczema
andor
famili
histori
asthma
patient
baselin
characterist
similar
two
treatment
arm
enrol
tabl
among
magnesium
recipi
geometr
mean
time
readi
discharg
h
ci
wherea
among
control
patient
h
ci
ratio
ci
p
fig
patient
subset
histori
eczema
andor
famili
histori
asthma
geometr
mean
durat
readi
discharg
h
ci
h
h
ci
h
magnesium
placebo
respect
ratio
p
fig
four
patient
receiv
placebo
one
magnesiumtr
patient
requir
icu
admiss
infirmari
p
mean
bronchiol
sever
score
baselin
discharg
similar
arm
overal
patient
group
patient
histori
eczema
andor
famili
histori
asthma
fig
secondari
outcom
patient
withdrawn
studi
apnea
cyanosi
hemodynam
instabl
blood
pressur
heart
rate
similar
magnesium
placebo
group
throughout
infirmari
stay
present
studi
found
benefit
ad
iv
magnesium
treatment
infant
bronchiol
even
patient
character
higher
risk
asthma
knowledg
trial
first
random
studi
investig
effect
iv
magnesium
popul
bronchiol
nebul
magnesium
test
bronchiol
previou
multicent
studi
report
nebul
magnesium
sulfat
epinephrin
compar
nebul
epinephrin
infant
moder
sever
bronchiol
patient
previou
repeat
cours
steroid
bronchodil
andor
famili
histori
asthma
exclud
although
signific
improv
respiratori
distress
assess
score
second
third
day
admiss
favor
nebul
magnesium
differ
found
length
stay
need
oxygen
second
small
trial
enrol
patient
moder
bronchiol
compar
nebul
magnesium
nebul
salbutamol
nebul
magnesium
sulfatesalbutamol
combin
signific
differ
wang
sever
score
h
favor
combin
aerosol
group
compar
nebul
magnesium
alon
group
p
given
uncertainti
clearcut
efficaci
fora
well
amount
magnesium
deliv
bynebul
magnesium
treatment
asthma
chose
use
iv
magnesium
present
studi
patient
need
hospit
admiss
wk
discharg
eczema
andor
famili
histori
asthma
histori
eczema
andor
famili
histori
asthma
data
present
unless
otherwis
indic
secondari
outcom
analysi
found
iv
magnesium
treatment
might
increas
risk
symptomat
relaps
among
patient
group
whole
especi
patient
eczema
andor
famili
histori
asthma
may
chanc
find
signific
p
valu
caus
us
concern
magnesium
treatment
infirmari
care
subset
might
mask
wors
bronchiol
patient
therefor
discharg
soon
may
somehow
prolong
diseas
cours
patient
also
possibl
bronchiol
treatment
practic
center
use
hyperton
salin
nebul
patient
system
dexamethason
select
patient
might
led
disadvantag
drug
interact
magnesium
intervent
group
neg
studi
may
fail
identifi
benefit
iv
magnesium
patient
subgroup
limit
sampl
size
howev
believ
find
generaliz
similarli
heterogen
group
patient
present
bronchiol
care
busi
urban
ed
iv
magnesium
provid
benefit
patient
acut
bronchiol
may
harm
